Latest News

Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Cardiovascular Safety and State-of-the-art Development Issues 2012: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity

March 2012

View article

QT Assessment in Early Clinical Development Can the Predictive Value be Enhanced to be Similar to That of a TQT study?

January 2012

View article

Further data to be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

November 2011

View article

Richmond Pharmacology enhances its established GE MUSE platform with the State-of-the-art Mortara 12-lead telemetry setup

November 2011

View article

Accelerating Early Phase Clinical Development in the UK:

October 2011

View article

RPL recently attended the 10th Annual Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT)

September 2011

View article

Low data variability

Exceptional ECG generation

Experts in cardiac safety

Our specialist services

News

Stay up to date with the latest activity at Richmond Pharmacology

Cardiovascular Safety and State-of-the-art Development Issues 2012: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity

QT Assessment in Early Clinical Development Can the Predictive Value be Enhanced to be Similar to That of a TQT study?

Further data to be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

Richmond Pharmacology enhances its established GE MUSE platform with the State-of-the-art Mortara 12-lead telemetry setup

Accelerating Early Phase Clinical Development in the UK:

RPL recently attended the 10th Annual Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT)

主要メンバー紹介

リッチモンドでのキャリア

動画紹介

Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme

Trial That Could Revolutionise Cardiac Safety Studies – Research Consortium Calls For Others To Join

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

私たちについて

ナレッジベース

ソーシャルメディア